Sagent Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SGNT)

$21.76 0.03 (0.14 %)
(As of 01/17/2018 04:22 AM ET)
Previous Close$21.73
Today's Range$21.74 - $21.76
52-Week Range$10.55 - $21.88
Volume260,400 shs
Average Volume607,514 shs
Market CapitalizationN/A
P/E Ratio-28.26
Dividend YieldN/A
BetaN/A

About Sagent Pharmaceuticals (NASDAQ:SGNT)

Sagent Pharmaceuticals logoSagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Receive SGNT News and Ratings via Email

Sign-up to receive the latest news and ratings for SGNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:SGNT
CUSIP78669210
Phone+1-847-9081604

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-28.2597402597403
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.77)
Net IncomeN/A
Net Margins-0.72%
Return on Equity-0.81%
Return on Assets-0.59%

Miscellaneous

EmployeesN/A
Outstanding Shares33,090,000

Sagent Pharmaceuticals (NASDAQ:SGNT) Frequently Asked Questions

What is Sagent Pharmaceuticals' stock symbol?

Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."

How were Sagent Pharmaceuticals' earnings last quarter?

Sagent Pharmaceuticals Inc (NASDAQ:SGNT) issued its quarterly earnings results on Tuesday, May, 3rd. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The company earned $67.30 million during the quarter, compared to analyst estimates of $74.30 million. Sagent Pharmaceuticals had a negative net margin of 0.72% and a negative return on equity of 0.81%. The business's revenue for the quarter was down 17.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.04 EPS. View Sagent Pharmaceuticals' Earnings History.

Who are some of Sagent Pharmaceuticals' key competitors?

How do I buy Sagent Pharmaceuticals stock?

Shares of Sagent Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sagent Pharmaceuticals' stock price today?

One share of Sagent Pharmaceuticals stock can currently be purchased for approximately $21.76.

How can I contact Sagent Pharmaceuticals?

Sagent Pharmaceuticals' mailing address is 1901 N Roselle Rd Ste 700, SCHAUMBURG, IL 60195-3194, United States. The company can be reached via phone at +1-847-9081604.


MarketBeat Community Rating for Sagent Pharmaceuticals (SGNT)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sagent Pharmaceuticals (NASDAQ:SGNT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AHold
Consensus Rating Score: N/AN/AN/A2.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Sagent Pharmaceuticals (NASDAQ:SGNT) Consensus Price Target History

Price Target History for Sagent Pharmaceuticals (NASDAQ:SGNT)

Sagent Pharmaceuticals (NASDAQ:SGNT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2016Deutsche BankDowngradeBuy -> HoldN/AView Rating Details
7/12/2016Raymond James FinancialDowngradeBuy -> Market PerformN/AView Rating Details
7/11/2016Royal Bank of CanadaDowngradeOutperform -> HoldN/AView Rating Details
7/11/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$22.00 -> $21.75N/AView Rating Details
6/17/2016Jefferies GroupReiterated RatingHold$13.00 -> $15.00N/AView Rating Details
6/1/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/AView Rating Details
5/9/2016Bank of AmericaReiterated RatingHold$13.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Sagent Pharmaceuticals (NASDAQ:SGNT) Earnings History and Estimates Chart

Earnings by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)

Sagent Pharmaceuticals (NASDAQ SGNT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2016Q1$0.01($0.15)$74.30 million$67.30 millionViewN/AView Earnings Details
2/16/2016Q415($0.02)($0.55)$78.13 million$83.10 millionViewListenView Earnings Details
11/3/2015Q315($0.07)$0.01$73.84 million$75.20 millionViewN/AView Earnings Details
8/4/2015Q215$0.05($0.01)$83.28 million$77.30 millionViewN/AView Earnings Details
5/5/2015Q115$0.04$0.04$80.63 million$82.60 millionViewN/AView Earnings Details
2/19/2015Q414$0.01$0.91$76.20 million$84.40 millionViewN/AView Earnings Details
11/4/2014Q314($0.04)$0.08$64.01 million$65.40 millionViewN/AView Earnings Details
7/30/2014Q214($0.01)$0.09$67.14 million$69.20 millionViewListenView Earnings Details
5/6/2014Q114($0.02)$0.16$65.66 million$70.90 millionViewListenView Earnings Details
2/11/2014Q4($0.01)$0.11$60.25 million$64.10 millionViewListenView Earnings Details
11/5/2013($0.03)$0.10ViewN/AView Earnings Details
8/6/2013Q2 2013$0.46$59.27 million$59.60 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)$0.34$55.31 million$60.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.20)($0.13)$48.60 million$49.40 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.26)($0.17)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.28)($0.30)ViewN/AView Earnings Details
2/16/2012Q4 2011($0.11)($0.33)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.12)($0.17)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.21)($0.37)ViewN/AView Earnings Details
5/13/2011Q1 2011($2.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sagent Pharmaceuticals (NASDAQ:SGNT) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sagent Pharmaceuticals (NASDAQ SGNT) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Institutional Ownership by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)

Sagent Pharmaceuticals (NASDAQ SGNT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/21/2016Ventures Fund V L.P. VivoMajor ShareholderSell2,005$13.55$27,167.75View SEC Filing  
11/4/2015Ventures Fund V L.P. VivoMajor ShareholderSell603,177$15.72$9,481,942.44View SEC Filing  
11/3/2015Vivo Ventures Vi, LlcMajor ShareholderSell67,283$16.32$1,098,058.56View SEC Filing  
11/2/2015Vivo Ventures Vi, LlcMajor ShareholderSell93,523$16.87$1,577,733.01View SEC Filing  
1/27/2015Morgan Stanley Investment ManaMajor ShareholderSell78,041$26.16$2,041,552.56View SEC Filing  
1/23/2015Morgan Stanley Investment ManaMajor ShareholderSell211,883$25.61$5,426,323.63View SEC Filing  
1/21/2015Morgan Stanley Investment ManaMajor ShareholderSell69,316$25.23$1,748,842.68View SEC Filing  
1/16/2015Morgan Stanley Investment ManaMajor ShareholderSell125,000$25.16$3,145,000.00View SEC Filing  
1/14/2015Morgan Stanley Investment ManaMajor ShareholderSell100,000$25.51$2,551,000.00View SEC Filing  
10/8/2014Robert J FlanaganDirectorSell16,000$31.56$504,960.00View SEC Filing  
10/7/2014Robert J FlanaganDirectorSell8,000$31.15$249,200.00View SEC Filing  
9/25/2014Robert J FlanaganDirectorSell16,000$30.01$480,160.00View SEC Filing  
9/24/2014Robert J FlanaganDirectorSell8,000$30.30$242,400.00View SEC Filing  
9/12/2014Robert J FlanaganDirectorSell16,000$28.30$452,800.00View SEC Filing  
9/11/2014Robert J FlanaganDirectorSell8,000$28.35$226,800.00View SEC Filing  
8/28/2014Robert J FlanaganDirectorSell16,000$27.19$435,040.00View SEC Filing  
8/27/2014Robert J FlanaganDirectorSell8,000$27.30$218,400.00View SEC Filing  
8/12/2014Robert J FlanaganDirectorSell16,000$24.39$390,240.00View SEC Filing  
7/31/2014Robert J FlanaganDirectorSell16,000$25.60$409,600.00View SEC Filing  
7/18/2014Robert J FlanaganDirectorSell16,000$26.18$418,880.00View SEC Filing  
7/2/2014Robert J FlanaganDirectorSell16,000$26.51$424,160.00View SEC Filing  
6/18/2014Robert J FlanaganDirectorSell16,000$23.37$373,920.00View SEC Filing  
6/4/2014Robert J FlanaganDirectorSell16,000$22.17$354,720.00View SEC Filing  
5/22/2014Robert FlanaganDirectorSell8,000$22.02$176,160.006,996View SEC Filing  
2/27/2014Michael LogerfoInsiderSell2,021$21.43$43,310.0333,011View SEC Filing  
10/3/2013Morgan Stanley Investment Manamajor shareholderSell47,826$20.27$969,433.02View SEC Filing  
9/26/2013Morgan Stanley Investment Manamajor shareholderSell67,965$20.37$1,384,447.05View SEC Filing  
9/25/2013Morgan Stanley Investment Manamajor shareholderSell48,124$21.30$1,025,041.20View SEC Filing  
9/23/2013Morgan Stanley Investment Manamajor shareholderSell119,557$21.83$2,609,929.31View SEC Filing  
9/19/2013Morgan Stanley Investment Manamajor shareholderSell88,885$22.53$2,002,579.05View SEC Filing  
9/16/2013Frank KungDirectorSell1,161,717$21.25$24,686,486.25View SEC Filing  
9/16/2013Jeffrey YordonCEOSell85,813$20.03$1,718,834.39669,036View SEC Filing  
9/16/2013Vivo Ventures Vi, Llcmajor shareholderSell622,700$21.25$13,232,375.00View SEC Filing  
8/12/2013Lorin DrakeVPSell1,000$23.69$23,690.0021,478View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sagent Pharmaceuticals (NASDAQ SGNT) News Headlines

Source:
DateHeadline
Contrasting Pfizer (PFE) and Sagent Pharmaceuticals (SGNT)Contrasting Pfizer (PFE) and Sagent Pharmaceuticals (SGNT)
www.americanbankingnews.com - January 10 at 1:16 AM
Critical Analysis: Sagent Pharmaceuticals (SGNT) & Lannett (LCI)Critical Analysis: Sagent Pharmaceuticals (SGNT) & Lannett (LCI)
www.americanbankingnews.com - December 31 at 8:26 AM
Sagent Pharmaceuticals (SGNT) and Tetraphase Pharmaceuticals (TTPH) Head-To-Head AnalysisSagent Pharmaceuticals (SGNT) and Tetraphase Pharmaceuticals (TTPH) Head-To-Head Analysis
www.americanbankingnews.com - November 24 at 11:40 PM
Corcept Therapeutics (CORT) and Sagent Pharmaceuticals (SGNT) Critical AnalysisCorcept Therapeutics (CORT) and Sagent Pharmaceuticals (SGNT) Critical Analysis
www.americanbankingnews.com - November 14 at 3:39 PM
Head-To-Head Survey: Dr. Reddys Laboratories (RDY) & Sagent Pharmaceuticals (SGNT)Head-To-Head Survey: Dr. Reddy's Laboratories (RDY) & Sagent Pharmaceuticals (SGNT)
www.americanbankingnews.com - November 11 at 11:26 PM
Sagent Pharmaceuticals (SGNT) vs. Astrazeneca PLC (AZN) Financial ReviewSagent Pharmaceuticals (SGNT) vs. Astrazeneca PLC (AZN) Financial Review
www.americanbankingnews.com - October 22 at 10:18 PM
Financial Review: Innocoll Holdings PLC (INNL) versus Sagent Pharmaceuticals (SGNT)Financial Review: Innocoll Holdings PLC (INNL) versus Sagent Pharmaceuticals (SGNT)
www.americanbankingnews.com - October 21 at 8:15 AM
Reviewing Sagent Pharmaceuticals (SGNT) & Its PeersReviewing Sagent Pharmaceuticals (SGNT) & Its Peers
www.americanbankingnews.com - October 20 at 12:22 PM
Analyzing Sagent Pharmaceuticals (SGNT) and Its CompetitorsAnalyzing Sagent Pharmaceuticals (SGNT) and Its Competitors
www.americanbankingnews.com - October 18 at 9:42 AM
Financial Analysis: Sagent Pharmaceuticals (SGNT) vs. Cellectar Biosciences (CLRB)Financial Analysis: Sagent Pharmaceuticals (SGNT) vs. Cellectar Biosciences (CLRB)
www.americanbankingnews.com - October 15 at 10:38 AM
Form 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman AnthonyForm 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman Anthony
www.streetinsider.com - September 1 at 7:13 PM
Nichi-Iko Pharmaceutical Co., Ltd.Nichi-Iko Pharmaceutical Co., Ltd.
www.thestreet.com - August 30 at 10:37 AM
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
au.finance.yahoo.com - August 29 at 7:14 PM
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of DelistSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist
biz.yahoo.com - August 29 at 7:14 PM
Form SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc.Form SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc.
www.streetinsider.com - August 9 at 7:41 PM
Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.
au.finance.yahoo.com - August 9 at 10:37 AM
SAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportSAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - August 5 at 7:38 PM

SEC Filings

Sagent Pharmaceuticals (NASDAQ:SGNT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sagent Pharmaceuticals (NASDAQ:SGNT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sagent Pharmaceuticals (NASDAQ SGNT) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.